ENTELLIGENCE is a program for clinical and basic science research in the field of cardiopulmonary medicine. The ENTELLIGENCE program provides opportunities for individual young investigators to promote quality medical care and enhance patients' lives by supporting research (basic science, clinical, or translational) in the area of pulmonary hypertension (PH) related to expanding our knowledge of the pathways involved in pulmonary vascular pathobiology.

The ENTELLIGENCE Young Investigators Award Program provides promising young investigators up to $100,000 in support to conduct basic science and clinical research via a 12-month mentored grant. Grants are awarded by the ENTELLIGENCE Steering Committee and based on scientific merit, originality, feasibility, and applicability to the diagnosis and treatment of PH. A condition of the grant application and funding is supervision by an appropriate mentor.

ENTELLIGENCE is funded by an independent grant by Actelion Pharmaceuticals US, Inc. All decisions to fund protocols are solely decided by the ENTELLIGENCE Steering Committee. Receipt of a grant in no way requires the recipient, nor implies that the recipient is obligated to, recommend or prescribe any Actelion products.

The ENTELLIGENCE Young Investigators Awards Program is part of a US-based program consistent with Actelion's commitment to basic science and clinical research in the area of PH. Investigator-initiated trials for young researchers will be supported if conducted at universities and research institutions in the United States and Canada.

With a strong commitment to research, ENTELLIGENCE provides a program for young investigators at institutions with research programs in cardiovascular medicine, pulmonology, and rheumatology to further explore PH.

Applicants are invited to submit original basic or clinical investigations specifically targeting pulmonary vascular disease in the following areas:

• Pathophysiology
• Pharmacology
• Treatment
• Genetics
• Diagnosis
• Epidemiology

The projects must be achievable within the time frame and budget allocation of the ENTELLIGENCE program. Therapeutic drug trials and pulmonary vascular disease registries will not be funded.

Initially, a Letter of Intent (LOI) is required for consideration of a proposal. If the LOI is accepted, an invitation to submit a full proposal is then requested. If your proposal is approved for funding, you and your mentor will be responsible for all aspects of your research. You will be provided with a grant application agreement, which you must sign and return within 90 days of notification of the award, along with the following documents:

• Institutional review/ethical committee approval for the submitted study (IRB)
• W-9 Form from the institution
• Study protocol
• Email and documentation sent to the site admistrator documenting the commencement of your research
• Sample informed consent documents, if necessary
• Institution animal care and use form (IACUC), if necessary

Please note, no funds will be disbursed prior to complete submission of the documents listed above. Failure to submit requested documents within the given time frame may result in the withdrawal of funds. By signing and submitting the grant application agreement, the principal investigator agrees that experiments conducted with funds from the ENTELLIGENCE Young Investigators Award Program are compliant with the ethical conduct of research as expressed in the latest version of the World Medical Association Declaration of Helsinki.

For more information please click Application Guidelines.